191 related articles for article (PubMed ID: 28480833)
1. Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy.
Beg S; Saini S; Imam SS; Rahman M; Swain S; Hasnain MS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):85-94. PubMed ID: 28480833
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of Tuberculosis.
Wais M; Aqil M; Goswami P; Agnihotri J; Nadeem S
Recent Pat Antiinfect Drug Discov; 2017; 12(2):107-119. PubMed ID: 28571549
[TBL] [Abstract][Full Text] [Related]
3. Present status of nanoparticle research for treatment of tuberculosis.
Shegokar R; Al Shaal L; Mitri K
J Pharm Pharm Sci; 2011; 14(1):100-16. PubMed ID: 21501557
[TBL] [Abstract][Full Text] [Related]
4. Nano-carriers for the Treatment of Tuberculosis.
Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
[TBL] [Abstract][Full Text] [Related]
6. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
9. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
Kaur M; Garg T; Rath G; Goyal AK
Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
[TBL] [Abstract][Full Text] [Related]
10. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
Pandey R; Khuller GK
Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
[TBL] [Abstract][Full Text] [Related]
11. Cavitation technology - a greener processing technique for the generation of pharmaceutical nanoemulsions.
Sivakumar M; Tang SY; Tan KW
Ultrason Sonochem; 2014 Nov; 21(6):2069-83. PubMed ID: 24755340
[TBL] [Abstract][Full Text] [Related]
12. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
Banyal S; Malik P; Tuli HS; Mukherjee TK
Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
[TBL] [Abstract][Full Text] [Related]
13. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
14. Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.
Nabi B; Rehman S; Aggarwal S; Baboota S; Ali J
Drug Deliv Transl Res; 2020 Aug; 10(4):1111-1121. PubMed ID: 32418158
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey R; Khuller GK
Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
18. Inhaled drug therapy for treatment of tuberculosis.
Misra A; Hickey AJ; Rossi C; Borchard G; Terada H; Makino K; Fourie PB; Colombo P
Tuberculosis (Edinb); 2011 Jan; 91(1):71-81. PubMed ID: 20875771
[TBL] [Abstract][Full Text] [Related]
19. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.
Gelperina S; Kisich K; Iseman MD; Heifets L
Am J Respir Crit Care Med; 2005 Dec; 172(12):1487-90. PubMed ID: 16151040
[TBL] [Abstract][Full Text] [Related]
20. Nano-based drug delivery optimization for tuberculosis treatment: A review.
Dahanayake MH; Jayasundera ACA
J Microbiol Methods; 2021 Feb; 181():106127. PubMed ID: 33359155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
